Kevin Punsky (@kevinpunsky)
Activity by Kevin Punsky
JACKSONVILLE, Fla. â€” Researchers on Mayo Clinicâ€™s Florida campus have been awarded a $13.3 million, five-year federal grant to test a vaccine designed to prevent the recurrence of triple-negative breast cancer, a subset of breast cancer for which there are no targeted therapies.
The clinical trial, which will enroll 280 patients at multiple clinical sites, is expected to begin early in 2016.
The grant, the Breakthrough Award from the U.S. Department of Defenseâ€™s Breast Cancer Research Program, will fund a national, phase II clinical trial testing the ability of a folate receptor alpha vaccine to prevent recurrence of this aggressive cancer following initial treatment.
Journalists: Sound bites with Dr. Knutson are available in the downloads.
MEDIA CONTACT: Kevin Punsky, Mayo Clinic Public Affairs,Â 507-284-5005, firstname.lastname@example.org [...]
JACKSONVILLE, Fla. â€” Cancer researchers dream of the day they can force tumor cells to morph back to the normal cells they once were. Now, researchers on Mayo Clinicâ€™s Florida campus have discovered a way to potentially reprogram cancer cells back to normalcy.
The finding, published in Nature Cell Biology, represents â€śan unexpected new biology that provides the code, the software for turning off cancer,â€ť says the studyâ€™s senior investigator, Panos Anastasiadis, Ph.D., chair of the Department of Cancer Biology on Mayo Clinicâ€™s Florida campus.
Journalists: Sound bites with Dr. Anastasiadis are available in the downloads.
JACKSONVILLE, Fla. â€” In their bid to find the best combination of therapies to treat anaplastic thyroid cancer (ATC), researchers on Mayo Clinicâ€™s Florida campus demonstrated that all histone deacetylase (HDAC) inhibitors are not created equal.
In testing multiple HDAC inhibitors in combination with the chemotherapy drug paclitaxel, known to give some benefit for this aggressive cancer, they found that class II HDAC inhibitors signal through a newly discovered pathway to promote synergy with chemotherapy treatment.
Journalists: Sound bites with Dr. Copland are available in the downloads.
JACKSONVILLE, Fla. â€” U.S. News & World Report again has named Mayo Clinicâ€™s Florida campus to its annual list of â€śAmericaâ€™s Best Hospitalsâ€ť published online today. Mayo Clinic is ranked No. 1 in the Jacksonville metro area, No. 4 in Florida and among the top 50 hospitals nationally in cancer, gastroenterology (GI) and GI surgery, geriatrics, and neurology and neurosurgery.
â€śThis honor reflects the deep commitment of our staff to provide the highest quality of care to our patients every day,â€ť says Gianrico Farrugia, M.D., CEO of Mayo Clinicâ€™s Florida campus. â€śOur employees are critical to the success of Mayo Clinic. Iâ€™m extremely grateful for their dedication and commitment to making the patient experience the very best it can be.â€ť
Journalists: Sound bites from Dr. Farrugia are available in the downloads.
JACKSONVILLE, Fla. â€” Researchers on Mayo Clinicâ€™s Florida campus have identified key differences between patients with sporadic amyotrophic lateral sclerosis (ALS or Lou Gehrigâ€™s disease) and those with the most common genetic form of ALS, a mutation in the C9orf72 gene.
Their findings, reported online today in Nature Neuroscience, demonstrate that ALS patients show abnormalities in levels and processing of ribonucleic acids (RNA), biological molecules that determine what gene information is used to guide protein synthesis.
More than 30,000 Americans live with ALS, a condition that destroys motor neuron cells that control essential muscle activity, such as speaking, walking, breathing and swallowing. While increasing efforts are geared toward therapeutic development, an effective drug for ALS has yet to be identified, in large part because of our incomplete understanding of the disease.
â€śOur results using advanced, modern laboratory techniques called next-generation sequencing, allowed us to acquire a library of new knowledge about patients with ALS,â€ť says the studyâ€™s senior author, Leonard Petrucelli, Ph.D., chair of the Department of Neuroscience on Mayo Clinicâ€™s Florida campus.
Dr. Petrucelli and Hu Li, Ph.D., assistant professor of pharmacology on Mayo Clinicâ€™s campus in Rochester, Minn., led a team of investigators who carefully analyzed the RNA from human brain tissues. They found that ALS brains had numerous RNA defects, compared to nondisease brains. They also predicted molecular events that may be altered due to the changes found in RNAs involved in pathways regulating those events and that may contribute to ALS.
JACKSONVILLE, Fla. â€” Clinicians testing the drug dasatinib, approved for several blood cancers, had hoped it would slow the aggressive growth of the deadly brain cancer glioblastoma; however, clinical trials to date have not found any benefit. Researchers at Mayo Clinic, who conducted one of those clinical trials, believe they know why dasatinib failed â€” and what to do about it.
In the online issue of Molecular Oncology, investigators report finding that dasatinib inhibits proteins that promote cancer growth as expected but also suppresses proteins that protect against cancer.
The findings suggest that pretesting patient glioblastoma biopsies will help identify who may respond well to dasatinib and who should avoid using the drug, says the studyâ€™s senior author, Panos Z. Anastasiadis, Ph.D., chair of the Department of Cancer Biology at Mayo Clinic in Florida.
JACKSONVILLE, Fla. â€” Mayo Clinic in Florida has been named a Pulmonary Hypertension Care Center by the Pulmonary Hypertension Association. The designation is given to centers that provide early diagnosis of pulmonary hypertension, a full range of therapies and specialized care, outcomes follow-up and clinical research and studies, among other points of excellence.
Mayo Clinic in Florida is the only Pulmonary Hypertension Care Center in the Southeast and one of only 26 in the country.
JACKSONVILLE, Fla., and SILVER SPRING, Md. â€” Mayo Clinic in Jacksonville, Florida, and United Therapeutics CorporationÂ (NASDAQ: UTHR) today announced a collaboration to build and operate a lung restoration center on the Mayo campus. The goal is to significantly increase the volume of lungs for transplantation by preserving and restoring selected marginal donor lungs, making them viable for transplantation. The restored lungs will be made available to patients at Mayo Clinic and other transplant centers throughout the United States.
Construction of the center is expected to be completed in late 2017. Financial details of the agreement were not disclosed.
â€śThis collaboration is exciting because it allows Mayo Clinic to bring the latest advances in life-saving technology to transplant patients,â€ť says Gianrico Farrugia, M.D., chief executive officer of Mayo Clinicâ€™s campus in Florida. â€śUltimately, this relationship will help Mayo Clinic expand its reach to patients who could benefit from this innovation. Increasing the number of lungs available for transplantation provides more options for patients suffering from pulmonary disease.â€ť
Journalists: Sound bites with Dr. Farrugia are available in the downloads.